Health Canada Currently Conducting Epidemiological Study Of These Incretin-Based Type 2 Diabetes Medications To Assess This Potential Drug Safety Issue
SUMMARY: Among the diabetes medications that fall into the incretin-based therapies class of drugs are:
- Bydureon (exenatide)
- Byetta (exenatide)
- Januvia (sitagliptin)
- Victoza (liraglutide)
We have written previously about the possible link between these diabetes drugs and cancer of the pancreas / pancreatic cancer.
From this article in the October 2014 edition of the Canadian Adverse Reaction Newsletter, “Incretin-based therapies and the risk of pancreatic cancer”, we learned that there is an epidemiological study being done by Health Canada to assess the potential association between pancreatic cancer and incretin-based diabetes drugs such as Bydureon, Byetta, Januvia, and Victoza.
[Read this article in full at original source]_____________________________________________________________________________
Bydureon / Byetta / Januvia / Victoza
Free Case Evaluation
Strictly Confidential, No Obligation
______________________________________________________________________________